Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If there are so many "consistent buys" then how come it's stuck at $.03. That tells more knowledgeable investors that the buys aren't so consistent.
Of course...
IMO,
Aussie
Trading...I've made money mucho times on FASC and posted my buy and sells each and every time so as not to be accused of having phantom buys (do you know they really exist?). At $.03, it could be time again. Just don't see the right info on the charts yet.
I've been associated with FASC longer than you and you're a long?
As for "KDS Micronex is in the right sector at the right time and with patents to back it up." Well, over the last ten years, hundreds of posts have made that claim. so far, it has yet to happen.
How in the world is FASC going to show it is a viable green energy company when it has failed in showing viability in every thing else?
Of course...
IMO.
Aussie
Australia is a beautiful place with wonderful people that just love Americans. You've got to go there some day. Give it a go Mate.
Jagster...My bets with you and the $1 lottery.
Why do you know some members of this board are referring to FASC as "...a 1 trick pony..."? Unfortunately, such companies don't go any where near %.50 when they're already below $.05.
Now some are also agreeing a R/S is inevitable. Rafael and I have been stating that for a couple years, only to be labeled "bashers."
Now FASC has added to an existing paten and the world again is new for FASC? Go figure.
Shame. FASC appears to have good technology that hasn't gone any where in over ten years.
IMO.
G' day Mate,
Aussie
tr...your very first post and it's not nice to accuse someone of "playing" board monitor? Could you kindly answer some of the questions in posts #s 10 & 11?
Of course...
IMO.
Aussie
Thank you to whomever re-posted my post. Especially, since it definitely dealt with "Alternative Green Energy Systems Inc (AGES)."
Aussie
What makes anyone want to believe FASC will be a successful GREEN ENERERGY/TECHNOLOGY company when they haven't been successful so far in any other arena?
Just because they updated a filed patent? LOL.
Now they have "...unique and innovative in creating alternative fuels from biomass..." Seems like these very words were used to describe many of FASC's other failed innovations. Now it's biomass' turn, or is it?
Of course...
IMO.
Aussie
FASC be such a "GreenEnergy/Technology company" as is being, IMO, falsely pportrayed, then how come it hasn't had any success?
How come when industries throughout the US and Canada and other countries go ofter such technologies, FASC isn't mentioned?
FASC has been "supposedly" involved with biomass for years, yet is not a viable company, why?
What happened with Prince George County? Weren't they over a year ago supposed to have purchased FASC KDS for their environmental purposes?
It's strange that the first company one would want to focus on is a failing company when there are so many much more successful companies out their with "acceptable" viable solutions. Or, is it?
Of course...
IMO.
Aussie
IMPORTANT! As you read the latest FASC PR, ask yourselves as you do DD on this comapny, "When was the last time a FASC PR actually came true?" ANSWER: NEVER. So, what's another meaningless patent going to do?
ATTENTION POTENTIAL BUYERS OF FASC!
Check out the following list, nothing has yet to materialize.
Can you name another company with as long a list of failures as FASC?
Do you really want to put your money into a company like this? And, remember, the list really goes back to 1995 and, still zip, zilch, zero.
Don't be surprised if some of the news seems to be repetitive or "RE-CYLED" LOL.
Jan. 23, 2002 Announces arrival of KDS equipment in Montreal in preparation for Exfor Pulp & Paper Exposition
Mar. 1, 2002 FIRST AMERICAN SCIENTIFIC CORP and THERMIX announce that Hydro-Quebec Capitech Inc, the investment capital division of energy giant Hydro Quebec, one of the worlds largest hydro-electric power producers, has joined Alternative Green Energy Systems Inc (AGES) as an equity partner with an initial investment of $1,000,000 to assist in research & development, marketing and operations.
Mar. 25, 2002 Sale of KDS equipment in Ireland to open new markets in organics waste processing May 30, 2002 Announces that AGES has entered into a contract with Hollywood Park Racetrack of Inglewood, California, to provide a preliminary engineering study to build an electrical co-generation system designed to operate on racetrack waste.
July 31, 2002 First American Scientific to attend Environment Japan 2002 Import Fair in Osaka sponsored by JETRO and BC Trade Mission
Nov. 25, 2002 Sale of 3 KDS systems to a Vancouver Island waste management and recycling firm
Dec. 10, 2002 Atlantic Packaging Products Ltd. signs letter of intent to purchase KDS equipment.
Feb. 5, 2003 First American Scientific Corp -Update on activities in Japan
Feb. 10, 2003 Announce receipt of an additional investment of $400,000 from HydroQuebec Capitech Inc.
June 12, 2003 Wins competition for research grant awarded by United States Department of Energy
Nov 24, 2003 Announces plans to build a production facility in Princeton, BC, to produce micronized zeolite
Feb 23, 2004 Announces sale of KDS Micronex to Atlas Mining Company
Apr 06, 2004 First American Scientific Corp. (OTCBB:FASC) Announces Signing of a $5,000,000 Contract with Halliburton Group Canada.
Apr 22, 2004 Laboratory results confirming Pathogen Kill in KDS Micronex
Apr 29, 2004 First American Scientific Corp. (OTCBB:FASC) Announces sale of KDS Micronex to Firma Codogni in Poland
Jun 7, 2004 First American Scientific Corp. finalizes joint venture agreement for the sale of KDS equipment in Malaysia
Jun 14, 2004 First American Scientific Corp. (OTCBB:FASC) announces site acquisition and commencement of construction of zeolite processing facility at Princeton B.C.
Jul 14, 2004 First American Scientific Corp. signs collaboration agreement with Mitsui in Japan
Jul 26, 2004 First American Scientific Corp. (FASC.OB) selected to participate with the University of Tennessee in USDA Biomass Research Initiative
Sep 9, 2004 First American Scientific Corp. (FASC.OB) signs US$1M funding agreement with WRAP in the U.K.
Oct 8, 2004 First American Scientific Corp (FASC - OTCBB) completes installation of KDS Micronex equipment in Utah and Poland
Oct 28, 2004 First American Scientific Corp. (FASC - OTCBB) and AGES announces SDTC grant approval for KDS 3000 construction and installation
Nov 9, 2004 First American Scientific Corp (FASC - OTCBB) announces completion of construction of its zeolite processing facility in Princeton B.C.
Dec 16, 2004 First American Scientific Corp. (OTCBB:FASC) takes counter measures to stop "naked shorting" of its stock
Jan 12, 2005 First American Scientific Corp. announces sale of KDS equipment under Waste & Resources Action Programme ( WRAP ) in the UK
Feb 9, 2005 First American Scientific Corp. (OTCBB: FASC) files KDS patents in Japan
Mar 23, 2005 First American Scientific Corp. announces sale of KDS Micronex equipment in Asia
Apr 1, 2005 Progress Report on WRAP project in the U.K.
Jun 20, 2005 First American Scientific Corp. announces sale and installation of KDS Micronex MF-777 at first biomass co-generation power plant in Malaysia
July 5, 2005 First American Scientific Corp announces funding agreement for project to install new KDS3000 system at Flakeboard Company Limited in Canada.
Oct 25, 2005 First American Scientific Corp (FASC - OTCBB) announces signing of exclusive agreement to license KDS technology in Japan
Nov 18, 2005 First American Scientific Corp. signs agreement to license KDS technology and set up demo facility in Korea
Jan 17, 2006 First American Scientific Corp (FASC - OTCBB) announces delivery of first KDS Micronex to Yokohama, Japan
Feb 2, 2006 First American Scientific Corp. (OTCBB: FASC) Sells First KDS System to JNK Heaters in South Korea
Apr 4, 2006 First American Scientific Corp Signs Distribution Agreement With EnergyCabin at Globe 2006 Environmental Conference
Apr 18, 2006 First American Scientific Corp (FASC - OTCBB) announces signing of Joint Venture Agreement to Introduce KDS Technology in Brazil, Uruguay and Argentina
May 18, 2006 First American Scientific Corp (FASC - OTCBB) Announces Sale of KDS Equipment to Be Installed at Waste Water Treatment Plant in Seoul, Korea
Oct 2, 2006 First American Scientific Corp. Announces Sale of KDS Micronex Equipment to Nutritech Solutions Ltd. (NTS)
Oct 9, 2006 First American Scientific Corp. (FASC -- OTCBB) Announces Sale of the EnergyCabin to Nakusp Energy Corp
Nov 7, 2006 First American Scientific Corp Announces Commencement of Pilot Project at Municipal Waste Treatment Facility in the City of Anyang, South Korea -- Is this for real or are they yinging and yanging shareholders once again? LOL.
Of course...
IMO.
Aussie
Australia is a beautiful place with wonderful people that just love Americans. You've got to go there some day. Give it a go Mate.
b9molecule...Just received a reply from PDEP's DeDe Sheel.
Hi Aussie,
I apologize for the delay in responding. I was out of town last week.
You are right, that would be a lot of shares to hit the market if all of the options were exercised.
The Company is hoping to have some news regarding one of its partners in the next couple of weeks; hopefully this can help counter any pressure on the stock price that might come from the exercise of the options.
DeDe
DeDe Sheel
San Francisco
One Front Street, 16th Floor
San Francisco, CA 94111
----------
Hope this helps.
G' day Mate,
Aussie
Blue...I had read it often in the past; but do not post on it. And, to tell the truth, until you mentioned it, I had forgotten about it. I do keep track of Australian stocks and any good ones I invest through my son-in-law who lives near Manly, Australia.
Thanks for the reminder.
I'll be traveling to Australia on Friday to visit my daughter and three grand children for a six weeks vacation.
G' day Mate,
Aussie
Stock price made a nice jump on 6/11/08 -- 0.45 0.05 12.50% -- PDEP. Read the latest PR (below), it looks to do better. PDEP also has a Prototype and Evaluation agreement with Samsung Electronics Corporation. And,it is backed by 49 approved patents and over 80 pending patents, this breakthrough in visualization is the first display technology that provides Actual Depth™. The Company has a sales, marketing and distribution license agreement with Sanyo Corporation (NASDAQ: SANYY) in Japan.
DO YOUR DD...
http://www.puredepth.com/
G' day Mates,
Aussie
THE PR:
IGT Launches Family of PureDepth MLD-powered Slot Machines
BUSINESS WIRE
Posted: 2008-06-11 09:36:39
REDWOOD SHORES, Calif.--(BUSINESS WIRE)----PureDepth, Inc. (OTC: PDEP) a global leader in next-generation display technologies and the pioneer of Multi-Layer Display (MLD(TM)) technology, today announced the first commercial implementation of its technology by longtime partner IGT (www.IGT.com), a global company specializing in the design, development, manufacturing, distribution and sales of computerized gaming machines and systems products.
IGT today announced the market launch of its REELdepth(TM) (www.IGT.com/ReelDepth) family of games, which are powered by PureDepth technology. The initial game rollout includes nearly 70 of IGT's familiar, top-performing classics, as well as several new AVP(R) (Advanced Video Platform) themes. In the fall, IGT intends to release the long-awaited Indiana Jones(TM) and the Last Crusade(TM) MegaJackpots(R) Slot, which debuted at the 2007 Global Gaming Expo (G2E).
"This is a very significant day for PureDepth, since we believe it underscores the commercial viability of PureDepth's MLD technology and demonstrates that MLD technology can be deployed by partners seeking to significantly enhance existing products or drive the rollout of new, exciting applications," said Jonathan McCaman, President of PureDepth.
The integration of MLD technology into IGT's product line yields a high-quality gaming experience, but also drives significant operator efficiencies. Because game and reel configuration are now dictated by players from their seats, operators who invest in REELdepth(TM) games no longer have to budget to change glass, change reel strips, or physically relocate and remove machines on the floor. REELdepth(TM) games have virtual reels that mimic the look and vibration of their mechanical counterparts, so traditional slot players are expected to feel comfortable playing them.
"It's nice to be able to give operators something they can't find anywhere else in the industry," said Ron Rivera, IGT Vice President of North American Sales. "Because we're the only gaming machine manufacturer offering this flexibility, our sales department receives calls regularly from slot directors wanting REELdepth(TM) games on their floors."
PureDepth believes that the launch by IGT is a successful milestone in an ongoing partnership between the two companies. Since early 2007, PureDepth's technical staff has worked in close collaboration with IGT's development team on hardware design, manufacturing support, and software development to ensure a successful product introduction. "IGT's rollout of their REELdepth(TM) family also underscores the tremendous partnership between the two companies, and our ability to work closely with licensees to ensure the successful execution of their product development and launch goals," concluded Mr. McCaman.
About PureDepth
PureDepth (www.puredepth.com) is an innovative technology company transforming the visual display experience by delivering award-winning MLD technology. Backed by 51 approved patents and over 80 pending patents, this breakthrough in visualization is the first display technology that provides Actual Depth(TM). The Company has a worldwide licensing agreement with Samsung Electronics Corporation (KSE:005930) (LSE: SMSN), a sales, marketing and distribution license agreement with Sanyo Corporation (NASDAQ: SANYY) in Japan, a worldwide licensing agreement with International Game Technology (NYSE: IGT) and business opportunities in broad consumer markets. Founded in 1999, the Company is headquartered in Redwood Shores, California, with a research and development center located in New Zealand and offices in Japan.
Forward-Looking Statements
This press release contains certain statements that are "forward-looking statements" and includes, among other things, discussions and disclosures of the Company's expectations for the use of its technology and market for its products, and the likelihood of any resulting products to become widely accepted by the marketplace. Words such as, but not limited to, "may," "likely," "anticipate," "expect" and "believes" indicate forward-looking statements. Although PureDepth believes that the expectations reflected in these forward-looking statements are generally reasonable, it can give no assurance that such expectations will ultimately prove to be correct or materialize. All phases of PureDepth's business and operations are subject to a number of uncertainties, risks and other influences, most of which are outside its control, and any one or combination of which could materially and adversely affect the results of the Company's operations, and whether any forward-looking statements contained herein ultimately prove to be accurate. Information regarding such risks and uncertainties can be found in the Company's most recently filed annual report on Form 10-KSB, interim report on Form 10-Q and other filings made by PureDepth with the SEC. PureDepth(TM), MLD(TM) and Actual Depth(TM) are trademarks of PureDepth, Inc. All other trademarks and registered trademarks are the property of their respective owners, without intent to infringe.
PureDepth, Inc.Media, analysts:Patrick Van de WilleFD Ashton Partners312-533-6704public-relations@puredepth.comorInvestor Relations:FD Ashton Partners, 650-361-0480investor-relations@puredepth.com
© Business Wire 2008
06/11/2008 08:30 ET
b9molecule...Can't answer at this time; however, I did send an email to the company just before writing this post. Will let you know their response.
G' day Mate,
Aussie
Stock price 0.45 0.05 12.50% -- PDEP -- nice little boosh. Read the latest PR (below), it looks to do better.
G' day Mates,
Aussie
THE PR:
IGT Launches Family of PureDepth MLD-powered Slot Machines
BUSINESS WIRE
Posted: 2008-06-11 09:36:39
REDWOOD SHORES, Calif.--(BUSINESS WIRE)----PureDepth, Inc. (OTC: PDEP) a global leader in next-generation display technologies and the pioneer of Multi-Layer Display (MLD(TM)) technology, today announced the first commercial implementation of its technology by longtime partner IGT (www.IGT.com), a global company specializing in the design, development, manufacturing, distribution and sales of computerized gaming machines and systems products.
IGT today announced the market launch of its REELdepth(TM) (www.IGT.com/ReelDepth) family of games, which are powered by PureDepth technology. The initial game rollout includes nearly 70 of IGT's familiar, top-performing classics, as well as several new AVP(R) (Advanced Video Platform) themes. In the fall, IGT intends to release the long-awaited Indiana Jones(TM) and the Last Crusade(TM) MegaJackpots(R) Slot, which debuted at the 2007 Global Gaming Expo (G2E).
"This is a very significant day for PureDepth, since we believe it underscores the commercial viability of PureDepth's MLD technology and demonstrates that MLD technology can be deployed by partners seeking to significantly enhance existing products or drive the rollout of new, exciting applications," said Jonathan McCaman, President of PureDepth.
The integration of MLD technology into IGT's product line yields a high-quality gaming experience, but also drives significant operator efficiencies. Because game and reel configuration are now dictated by players from their seats, operators who invest in REELdepth(TM) games no longer have to budget to change glass, change reel strips, or physically relocate and remove machines on the floor. REELdepth(TM) games have virtual reels that mimic the look and vibration of their mechanical counterparts, so traditional slot players are expected to feel comfortable playing them.
"It's nice to be able to give operators something they can't find anywhere else in the industry," said Ron Rivera, IGT Vice President of North American Sales. "Because we're the only gaming machine manufacturer offering this flexibility, our sales department receives calls regularly from slot directors wanting REELdepth(TM) games on their floors."
PureDepth believes that the launch by IGT is a successful milestone in an ongoing partnership between the two companies. Since early 2007, PureDepth's technical staff has worked in close collaboration with IGT's development team on hardware design, manufacturing support, and software development to ensure a successful product introduction. "IGT's rollout of their REELdepth(TM) family also underscores the tremendous partnership between the two companies, and our ability to work closely with licensees to ensure the successful execution of their product development and launch goals," concluded Mr. McCaman.
About PureDepth
PureDepth (www.puredepth.com) is an innovative technology company transforming the visual display experience by delivering award-winning MLD technology. Backed by 51 approved patents and over 80 pending patents, this breakthrough in visualization is the first display technology that provides Actual Depth(TM). The Company has a worldwide licensing agreement with Samsung Electronics Corporation (KSE:005930) (LSE: SMSN), a sales, marketing and distribution license agreement with Sanyo Corporation (NASDAQ: SANYY) in Japan, a worldwide licensing agreement with International Game Technology (NYSE: IGT) and business opportunities in broad consumer markets. Founded in 1999, the Company is headquartered in Redwood Shores, California, with a research and development center located in New Zealand and offices in Japan.
Forward-Looking Statements
This press release contains certain statements that are "forward-looking statements" and includes, among other things, discussions and disclosures of the Company's expectations for the use of its technology and market for its products, and the likelihood of any resulting products to become widely accepted by the marketplace. Words such as, but not limited to, "may," "likely," "anticipate," "expect" and "believes" indicate forward-looking statements. Although PureDepth believes that the expectations reflected in these forward-looking statements are generally reasonable, it can give no assurance that such expectations will ultimately prove to be correct or materialize. All phases of PureDepth's business and operations are subject to a number of uncertainties, risks and other influences, most of which are outside its control, and any one or combination of which could materially and adversely affect the results of the Company's operations, and whether any forward-looking statements contained herein ultimately prove to be accurate. Information regarding such risks and uncertainties can be found in the Company's most recently filed annual report on Form 10-KSB, interim report on Form 10-Q and other filings made by PureDepth with the SEC. PureDepth(TM), MLD(TM) and Actual Depth(TM) are trademarks of PureDepth, Inc. All other trademarks and registered trademarks are the property of their respective owners, without intent to infringe.
PureDepth, Inc.Media, analysts:Patrick Van de WilleFD Ashton Partners312-533-6704public-relations@puredepth.comorInvestor Relations:FD Ashton Partners, 650-361-0480investor-relations@puredepth.com
© Business Wire 2008
06/11/2008 08:30 ET
PUREDEPTH INC (PDEP)
Stock price 0.45 0.05 12.50%
Today's news (below) gives this just a little lift; however, the future definitely looks real good. Do your DD.
G' day Mates,
Aussie
THE PR:
IGT Launches Family of PureDepth MLD-powered Slot Machines
BUSINESS WIRE
Posted: 2008-06-11 09:36:39
REDWOOD SHORES, Calif.--(BUSINESS WIRE)----PureDepth, Inc. (OTC: PDEP) a global leader in next-generation display technologies and the pioneer of Multi-Layer Display (MLD(TM)) technology, today announced the first commercial implementation of its technology by longtime partner IGT (www.IGT.com), a global company specializing in the design, development, manufacturing, distribution and sales of computerized gaming machines and systems products.
IGT today announced the market launch of its REELdepth(TM) (www.IGT.com/ReelDepth) family of games, which are powered by PureDepth technology. The initial game rollout includes nearly 70 of IGT's familiar, top-performing classics, as well as several new AVP(R) (Advanced Video Platform) themes. In the fall, IGT intends to release the long-awaited Indiana Jones(TM) and the Last Crusade(TM) MegaJackpots(R) Slot, which debuted at the 2007 Global Gaming Expo (G2E).
"This is a very significant day for PureDepth, since we believe it underscores the commercial viability of PureDepth's MLD technology and demonstrates that MLD technology can be deployed by partners seeking to significantly enhance existing products or drive the rollout of new, exciting applications," said Jonathan McCaman, President of PureDepth.
The integration of MLD technology into IGT's product line yields a high-quality gaming experience, but also drives significant operator efficiencies. Because game and reel configuration are now dictated by players from their seats, operators who invest in REELdepth(TM) games no longer have to budget to change glass, change reel strips, or physically relocate and remove machines on the floor. REELdepth(TM) games have virtual reels that mimic the look and vibration of their mechanical counterparts, so traditional slot players are expected to feel comfortable playing them.
"It's nice to be able to give operators something they can't find anywhere else in the industry," said Ron Rivera, IGT Vice President of North American Sales. "Because we're the only gaming machine manufacturer offering this flexibility, our sales department receives calls regularly from slot directors wanting REELdepth(TM) games on their floors."
PureDepth believes that the launch by IGT is a successful milestone in an ongoing partnership between the two companies. Since early 2007, PureDepth's technical staff has worked in close collaboration with IGT's development team on hardware design, manufacturing support, and software development to ensure a successful product introduction. "IGT's rollout of their REELdepth(TM) family also underscores the tremendous partnership between the two companies, and our ability to work closely with licensees to ensure the successful execution of their product development and launch goals," concluded Mr. McCaman.
About PureDepth
PureDepth (www.puredepth.com) is an innovative technology company transforming the visual display experience by delivering award-winning MLD technology. Backed by 51 approved patents and over 80 pending patents, this breakthrough in visualization is the first display technology that provides Actual Depth(TM). The Company has a worldwide licensing agreement with Samsung Electronics Corporation (KSE:005930) (LSE: SMSN), a sales, marketing and distribution license agreement with Sanyo Corporation (NASDAQ: SANYY) in Japan, a worldwide licensing agreement with International Game Technology (NYSE: IGT) and business opportunities in broad consumer markets. Founded in 1999, the Company is headquartered in Redwood Shores, California, with a research and development center located in New Zealand and offices in Japan.
Forward-Looking Statements
This press release contains certain statements that are "forward-looking statements" and includes, among other things, discussions and disclosures of the Company's expectations for the use of its technology and market for its products, and the likelihood of any resulting products to become widely accepted by the marketplace. Words such as, but not limited to, "may," "likely," "anticipate," "expect" and "believes" indicate forward-looking statements. Although PureDepth believes that the expectations reflected in these forward-looking statements are generally reasonable, it can give no assurance that such expectations will ultimately prove to be correct or materialize. All phases of PureDepth's business and operations are subject to a number of uncertainties, risks and other influences, most of which are outside its control, and any one or combination of which could materially and adversely affect the results of the Company's operations, and whether any forward-looking statements contained herein ultimately prove to be accurate. Information regarding such risks and uncertainties can be found in the Company's most recently filed annual report on Form 10-KSB, interim report on Form 10-Q and other filings made by PureDepth with the SEC. PureDepth(TM), MLD(TM) and Actual Depth(TM) are trademarks of PureDepth, Inc. All other trademarks and registered trademarks are the property of their respective owners, without intent to infringe.
PureDepth, Inc.Media, analysts:Patrick Van de WilleFD Ashton Partners312-533-6704public-relations@puredepth.comorInvestor Relations:FD Ashton Partners, 650-361-0480investor-relations@puredepth.com
© Business Wire 2008
06/11/2008 08:30 ET
Australia is a beautiful place with wonderful people that just love Americans. You've got to go there some day. Give it a go Mate.
Sinko de Mayo.
Most people don’t know that back in 1912, Hellmann’s Mayonnaise was manufactured in England.
In fact, the Titanic was carrying 120,000 jars of the condiment scheduled for delivery in Vera Cruz, Mexico, which was to be the next port of call for the great ship after its stop in New York.
This would have been the largest single shipment of mayonnaise ever delivered to Mexico.
But as we know, the great ship did not make it to New York. It hit an iceberg and sank, and the cargo was forever lost.
The people of Mexico, who were crazy about mayonnaise, and were eagerly awaiting its delivery, were devastated at the loss.
Their anguish was so great, that they declared a National Day of Mourning, which they still observe to this day.
The National Day of Mourning occurs each year on May 5th and is known, of course, as:
Sinko de Mayo.
-------------------------------------------------------------
Have a great day.
Aussie
Sorry, seems like I missed putting the HTML in the post. Here goes:
http://www.videonewswire.com/VWP/Player/advplayer.html?id=47313&uid=2336866&time=GEEMEIFNEGIGJH&digest=NTIdWLzDKN3PT5EhNEcm4g
G' day Mates,
Aussie
SGN...Might well rise in the coming quarters. According to their CEO, SGN is expected to conservatively bring in $40 + million in the coming quarters. However, as with any penny stock, PRs and webcast are self-serving. So, do your DD.
Here's the link for the webcast for those who care to view it.
SGN currently at $.76.
G' day Mates,
Aussie
Here's a place you guys can take your spouses for a fine breath taking dinner.
http://dinnerinthesky.com/pictures.php
http://dinnerinthesky.com/
Bon appetite!
G' day Mates,
Aussie
Boosh as booshers go is now a swoosh. But, you may still want to keep an eye on it.
G' day Mates,
Aussie
SGN...Could it be making another boosh? Yesterday it went up $.20. today so far it is up another $.03.
G' day Mates,
Aussie
PDEP had a nice lift a couple days ago. Now comes news that could interest investors. Samsung is an interesting partner to have.
PureDepth MLD Technology Displayed at CeBIT
"Actual Depth" 3-D Multi-Layer Display technology showcased by Samsung at Europe's biggest technology trade show
REDWOOD SHORES, Calif., Mar 07, 2008 (BUSINESS WIRE) -- PureDepth, Inc. (OTC: PDEP) a global leader in next-generation display technologies and the pioneer of Multi-Layer Display (MLD(TM)) technology, announced today that the company's MLD technology is being displayed at CeBIT, Europe's largest technology expo, by PureDepth's partner Samsung Electronics Corporation (KSE:005930) (LSE:SMSN).
PureDepth's display - adjacent to Samsung's groundbreaking 80-inch flat panel display - includes two units which focus on the technology's application in larger, public information displays (kiosks, advertising, etc.). The units are 20.1-inch dual-layer displays, with touchscreen capabilities.
The PureDepth display at the Samsung booth results from a licensing agreement between Samsung and PureDepth signed in October 2007, which provides for Samsung's development of mass market applications based on PureDepth's patented MLD technology. That agreement was followed in November with an agreement between the PureDepth and the Samsung LCD Business to jointly explore opportunities in the mobile market.
CeBIT is the world's largest trade fair showcasing digital IT and telecommunications solutions for home and work environments, serving industry players in the wholesale/retail sector, skilled trades, banks, the services sector, government agencies and science. CeBIT offers an international platform for comparing notes on current industry trends, networking, and product presentations. CeBIT is currently being held in Hannover, Germany and continuing through March 9.
About PureDepth
PureDepth (www.puredepth.com) is an innovative technology company transforming the visual display experience by delivering award-winning MLD technology. Backed by 50 approved patents and over 80 pending patents, this breakthrough in visualization is the first display technology that provides Actual Depth(TM). The Company has a worldwide licensing agreement with Samsung Electronics Corporation (KSE:005930) (LSE: SMSN), a sales, marketing and distribution license agreement with Sanyo Corporation (NASDAQ: SANYY) in Japan, a worldwide licensing agreement with International Game Technology (NYSE: IGT) and business opportunities in broad consumer markets. Founded in 1999, the Company is headquartered in Redwood Shores, California, with a research and development center located in New Zealand and offices in Japan.
Forward-Looking Statements
This press release contains certain statements that are "forward-looking statements" and includes, among other things, discussions and disclosures of the Company's expectations for the use of its technology and market for its products, and the likelihood of any resulting products to become widely accepted by the marketplace. Words such as, but not limited to, "may," "likely," "anticipate," "expect" and "believes" indicate forward-looking statements. Although PureDepth believes that the expectations reflected in these forward-looking statements are generally reasonable, it can give no assurance that such expectations will ultimately prove to be correct or materialize. All phases of PureDepth's business and operations are subject to a number of uncertainties, risks and other influences, most of which are outside its control, and any one or combination of which could materially and adversely affect the results of the Company's operations, and whether any forward-looking statements contained herein ultimately prove to be accurate. Information regarding such risks and uncertainties can be found in the Company's most recently filed annual report on form 10-KSB, interim report on form 10-QSB and other filings that have been made with the SEC. PureDepth(TM), MLD(TM) and Actual Depth(TM) are trademarks of PureDepth, Inc. All other trademarks and registered trademarks are the property of their respective owners, without intent to infringe.
SOURCE: PureDepth, Inc.
PureDepth, Inc.
Investor Relations:
FD Ashton Partners, 650-361-0480
investor-relations@puredepth.com
Copyright Business Wire 2008
News Provided by COMTEX
------------------------------------------------------------
G' day Mates,
Aussie
Actually, the beginning of last May and June, PDEP was at its high of about $2.25. since then it has been in a down trend and lately it's been erratic. As far as the charts go on this one, none of them favor buying PDEP at all. And, I usually do a 10/20/30 SMA(10 & 20 are well below the 30), Volume+, On-Balance-Volume and a Williams%R on all stocks .
Personally, it is one of them that has a technology that screams huge potential within the gaming and phone industries especially.
I've only shown the booshes on the board for PDEP, as to hype it in any way would be completely misleading. There is no way to fundamentally or as a chartist that this stock leads shareholders to run out and buy it. It's just one of those that after reading their technology PRs and website, you get the feeling if any penny stock should have a really good and sudden uptrend someday, it's the one. Otherwise, it's do your DD on it real good.
G' day Mate,
Aussie
PUREDEPTH INC (PDEP)
0.40 +0.13 (+48.15%)
Can't explain the sudden jump up, as there is no news out there.
G' day Mates,
Aussie
A boosher...
PUREDEPTH INC (PDEP)
0.40 +0.13 (+48.15%)
G' day Mates,
Aussie
Makes one want to go out and buy one of three Volkswagen stocks.
Currently priced at:
VLKAY -- 45.50
VLKAF -- 221.00
VLKPY -- 27.35
G' day Mate,
Aussie
Ronnies...Don't blame you. With ENCY you lucked out and had some profit. Hopefully your next endeavor is much, much better.
Here are two companies that have really good products and, IN MY OPINION, great potential. It's the potential and their customer base you want to look at. I have included their websites for your DD and convenience.
PureDepth ™
http://www.puredepth.com/
Signalife Clear Data
http://www.signalife.com/index.asp
SGN went up $.14 yesterday; but, don't let that fool you. It has done that before. Presently, their charts, in a word, suck.
G' day Mate,
Aussie
waitedg...
You made believing the truth hard in the first place, not I. My truths have never been thrown back in my face, because the truth stands up.
Obviously I read the whole profile that was shown. I guess it's believable, with you who knows.
Your main problem was trying the religious mumbo jumbo bit and being down right hypocritical with your subsequent postings. Those type of posters aren't believable no matter what they post.
If you notice, you were only chided on your age posted, not on your medical situation(only the longs on the FASC RB board stoop that low). And, in respects to your situation it is somewhat of a shame as I am sure you are telling the truth. Al bi et, penny posting boards are not the proper place to seek comfort or sympathy, especially since not one single poster on any board is really known or have been personally met. In all my postings, I have truly only met just one: that being Rafael.
As for IDSM, it is what it is, for the time being, one just to be played with as it goes up to about $.30 then drops down to about $.14. It is too risky. Who knows, if or when, a real steady rise will happen. The last year shows the stock to be very erratic. I believe it was Megster who first brought it to my attention and I have been watching it ever since; but, have stayed away from it, as the charts never have shown a true buy signal at all. Good luck to those who believe in it.
Of course...
IMO.
Aussie
Waitedg...In your post, you say you're 81 ("...Am 81 years old...". Now in going back to your profile which was established in 1999 on RB, you were then 65. That was only 9 years ago. How is it you are now 81?? Hard to separate the truth from fiction when you post.
http://ragingbull.quote.com/mboard/memalias.cgi?member=Waitedg
New time frame for aging?
Of course...
IMO.
Aussie
UPDATE 1-Pfizer says to buy Encysive and Thelin lung drug --Wed Feb 20, 2008 11:10am ET
By Ransdell Pierson
NEW YORK, Feb 20 (Reuters) - Pfizer Inc (PFE.N: Quote, Profile , Research) on Wednesday said it has agreed to pay about $195 million to acquire Encysive Pharmaceuticals Inc (ENCY.O: Quote, Profile , Research) and its Thelin lung-disorder medicine that has repeatedly failed to win U.S. approval.
Pfizer, which badly needs new medicines to offset sales declines for its drugs facing generic competition, said it will make a cash offer for all Encysive shares at $2.35 apiece, for an equity value of $195 million. That is more than double Encysive's closing share price on Tuesday of $1.08.
Pfizer said it has also agreed to assume Encysive's change of control repurchase obligations under its 2.5 percent convertible senior notes.
The U.S. Food and Drug Administration has issued three approvable letters for Thelin, which is used to treat pulmonary arterial hypertension, without allowing it to come to market.
The often-fatal condition is characterized by very high blood pressure in the arteries between the lungs and heart and is estimated to affect about 100,000 people in North America and Europe.
"Pfizer plans to conduct a pivotal Phase III trial to support registration in the U.S." of Thelin, Pfizer said in its release, noting that the drug is already approved in the European Union, Australia and Canada.
Thelin is a once-daily pill that works through a different mechanism than Pfizer's own approved Revatio treatment for pulmonary arterial hypertension.
The Encysive drug blocks receptors to the protein endothelin that causes a tightening of blood vessels.
Revatio, which has the same active ingredient as Pfizer's widely used Viagra anti-impotence treatment, relaxes smooth muscle cells lining blood vessels and thereby improves blood flow to particular areas of the body.
"The acquisition of Encysive will add growing, near-term revenue from the European market and increase our already strong presence in the cardio-respiratory arena with a product that complements Revatio," said Ian Read, Pfizer's president of pharmaceutical operations.
Shares of Swiss drugmaker Actelion (ATLN.VX: Quote, Profile , Research), whose marketed Tracleer drug is a rival treatment for the lung condition, fell as much as much as 3.3 percent after Pfizer announced its intention to buy Encysive.
"Actelion is coming off on this because (the) market was speculating Pfizer could bid for Actelion and one might see Pfizer's marketing power as a threat to Tracleer," one trader said.
Pfizer shares were little changed in morning trading on the New York Stock Exchange, amid a moderate downturn for the drug sector. Encysive shares soared 110 percent, or $1.19, to $2.27, on the Nasdaq.
--------------------------
G' day Mates,
Aussie
Roonies...Actually, I had sold ENCY at $4.25 back in July when it started to go down. Turned out to be a good move.
Now it seems investors may make an even better buck on it as it is being bought out by Pfizer Inc $195 million on Wednesday.
http://today.reuters.com/news/articlehybrid.aspx?type=comktNews&rpc=33&storyid=2008-02-21T170705Z_01_WLB7559_RTRIDST_0_GILEAD-EUROPE-URGENT.XML
There has been news out lately -- nothing earth shattering.
G'd luck with it.
G' day Mate,
Aussie
ENCY went from $1.08 to $2.27 on yesterday's news. Hope some of you got on that.
Pfizer to Acquire Encysive Pharmaceuticals
BUSINESS WIRE
Posted: 2008-02-20 09:26:41
NEW YORK & HOUSTON--(BUSINESS WIRE)----Pfizer Inc today announced that it has entered into an agreement to acquire Encysive Pharmaceuticals Inc. (NASDAQ: ENCY), a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) is commercially available in much of the European Union and is approved in other markets.
http://money.aol.com/news/articles/_a/pfizer-to-acquire-encysive/n20080220092609990094
G' day Mates,
Aussie
WAITEDG...
techisbest wrote something in response to a similar post you made on FASC and another Ihub board. His kind words were,
"Spend most of it with those who are important in your life.
I hope this is a time of reflection and comfort for you."
FASC and stocks in general shouldn't be as important as your life. Such an important message you overshadowed with a half-meant and half-hearted apology and your anxiety to buy a less than two cent stock. The importance of your real message got clouded.
If you want and really seek the Lord's help, then leave that impression so posters may add you to their prayers. Keep other subversive subliminal messages out. I won't say any more about religion, as you are well aware of how I think about you and religion. You message didn't change that one iota.
Don't really know and can't really tell by your message how much time you have. Whatever the time, even at 81, it should be used judiciously.
Of course...
IMO.
Aussie
ENCY went from $1.08 to $2.28 on today's news.
Pfizer to Acquire Encysive Pharmaceuticals
BUSINESS WIRE
Posted: 2008-02-20 09:26:41
NEW YORK & HOUSTON--(BUSINESS WIRE)----Pfizer Inc today announced that it has entered into an agreement to acquire Encysive Pharmaceuticals Inc. (NASDAQ: ENCY), a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) is commercially available in much of the European Union and is approved in other markets.
http://money.aol.com/news/articles/_a/pfizer-to-acquire-encysive/n20080220092609990094
G' day Mates,
Aussie
AVANIR Reports First Quarter Fiscal 2008 Financial Results
Continued Progress with Zenvia™ Development
AVANIR Pharmaceuticals (NASDAQ:AVNR) today reported financial results for the three months ended December 31, 2007.
For the first quarter of fiscal 2008, AVANIR reported a net loss of $5.5 million, or $0.13 per share, compared with a net loss of $13.6 million, or $0.39 per share, for the first quarter of fiscal 2007. Total net revenues for the first quarter of fiscal 2008 were $2.1 million. Total operating expenses were $6.6 million in the first quarter of fiscal 2008, compared with $14.6 million in the comparable fiscal 2007 period. Operating expenses for the first quarter of fiscal 2008 included expenses associated with the initiation of the Zenvia (dextromethorphan/quinidine [DM/Q]) Phase III confirmatory STAR trial. Cash used in operations during the first quarter of fiscal 2008 was $4.1 million.
"We continue to make progress with our Zenvia clinical programs, reflecting our mission to bring this product candidate to market as quickly and safely as possible," said Dr. Randall Kaye, AVANIR's Chief Medical Officer. "Since commencing our confirmatory Phase III clinical trial ("STAR" trial) in pseudobulbar affect (PBA) in mid-December, we continue to gain momentum in activating study sites and enrolling patients. We remain on track to deliver top-line data in the second half of calendar 2009. Our large formal pharmacokinetic (PK) study for the diabetic peripheral neuropathic (DPN) pain program is also well underway. We consider this PK study an important step in identifying an alternative Zenvia formulation for our next Phase III trial in DPN pain. We have initiated dosing for all cohorts in the study and now expect to announce top-line results for this PK study during the second calendar quarter of 2008."
"In addition to advancing our clinical programs, we are also making progress toward improving the Zenvia intellectual property portfolio. In November, AVANIR received official notification from the European Patent Office (EPO) of its intent to grant a new patent, prolonging the protection of Zenvia in Europe for both the PBA and DPN pain indications until 2023. We have a corresponding patent application pending with the U.S. Patent and Trademark Office and based on the outcome in Europe, we are optimistic of a positive response in the U.S. as well," said Keith Katkin, AVANIR's President and CEO.
RECENT HIGHLIGHTS AND UPCOMING MILESTONES:
CLINICAL PROGRAMS AND PIPELINE
Zenvia in PBA
Reached a definitive agreement with the U.S. Food and Drug Administration (FDA), under the special protocol assessment (SPA) process, on the design of a single confirmatory Phase III clinical trial with Zenvia in patients with PBA, referred to as the STAR trial.
Initiated enrollment of PBA patients in the STAR trial. AVANIR is on schedule to complete enrollment in the first half of calendar year 2009 and to report top-line data in the second half of calendar year 2009.
Zenvia in DPN Pain
Initiated a large, formal PK study to assess alternative lower-dose quinidine formulations of Zenvia for DPN pain intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested. Dosing of the first three cohorts of subjects with varying regimens of dextromethorphan and quinidine has been completed. The last two dosage cohorts have been initiated. AVANIR expects to release top-line results during the second quarter of calendar 2008.
COMPANY OPERATIONS
Received official communication from the EPO, under Rule 51(4) EPC, that the EPO intends to grant AVANIR's pending Zenvia patent for both PBA and DPN pain. Issuance of this patent will extend the patent life of Zenvia in Europe through 2023.
Announced that the Annual Meeting of Shareholders will be held Thursday, February 21, 2008 in Irvine, California.
BALANCE SHEET HIGHLIGHTS
As of December 31, 2007, AVANIR had cash and investments in securities totaling $29.4 million, including cash and cash equivalents of $28.3 million, investments of $250,000 and restricted investments in securities of $857,000.
Conference Call and Webcast
Management will host a conference call with a simultaneous webcast today beginning at 11:00 a.m. Eastern time / 8:00 a.m. Pacific time to discuss its financial results and recent business developments. The call will feature Keith Katkin, President and Chief Executive Officer; Randall Kaye, MD, Senior Vice President and Chief Medical Officer; and Christine Ocampo, Corporate Controller to discuss financial results and answer questions. Investors are invited to listen to the live webcast by visiting AVANIR's corporate website at www.avanir.com.
An archived copy of the webcast will be available on AVANIR's website for 30 days, and a telephone replay will be available through February 12, 2008, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 31867395.
About Zenvia
Zenvia is a combination of two well-characterized compounds: the therapeutically active ingredient dextromethorphan and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways: through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. In October 2006, the Company received an approvable letter for Zenvia in the treatment of PBA. The Company has initiated a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) utilizing a new lower quinidine dose formulation of Zenvia intended to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. For more information about the STAR trial visit http://www.pbatrial.com and for more information about the Agency's SPA process see http://www.fda.gov/cder/guidance/3764fnl.htm. In April 2007, AVANIR announced successfully meeting all primary endpoints in a Phase III study of Zenvia in DPN pain. The Company is conducting a formal pharmacokinetic (PK) study to assess alternative lower-dose quinidine formulations of Zenvia for DPN pain that are intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication.
About AVANIR
AVANIR Pharmaceuticals is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and is the subject of an approvable letter from the U.S. Food and Drug Administration (FDA) for that indication. The Company has initiated a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the FDA utilizing a new lower quinidine dose formulation of Zenvia intended to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. Additionally, in April 2007 AVANIR announced meeting all primary endpoints in a Phase III clinical trial with Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. The Company is conducting a formal pharmacokinetic (PK) study to assess alternative lower-dose quinidine formulations of Zenvia for DPN pain that are intended to deliver similar efficacy and improve safety/tolerability versus the formulations previously tested for this indication. AVANIR has also licensed a compound to Novartis International Pharmaceuticals Ltd. for the treatment of inflammatory disease. AVANIR's infectious disease drug candidate, AVP-21D9, is a human monoclonal antibody in pre-clinical development for the treatment of anthrax with funding provided to date from NIH/NIAID grants. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
Forward Looking Statements
Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that the Company will be able to complete clinical trials and the pharmacokinetic (PK) study within the projected time periods. There can also be no assurance that the PK study will identify one or more new doses of Zenvia that have the desired efficacy and an acceptable safety/tolerability profile, or that the U.S. Food and Drug Administration (FDA) will approve Zenvia for any indication. Risks and uncertainties affecting the Company's financial condition and operations also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent to update these forward-looking statements.
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0
http://www.b2i.us/View.asp?b=958&ID=48352&I=30299
-----------------------
G' day Mates,
Aussie
b9...Don't know if PHPG is a true boosher (not that it really matters -- hmmm! Same can be said for SGN, LOL.); but, I have had my eye on it.
The right side of the chart has definitely formed the right side of a cup. It will be interesting to see if it develops a true buy point. The 10 & 20 SMA are on the verge of breakimg through the 30 SMA, which as you know is a very bullish sign. The OBV is also in a very bullish position. The volume as of late has been very erratic. I also like the looks of your charts.
G' day Mate,
Aussie
today = two day.
SGN finished up $.095 today for a today gain of $.205. That's basically a 47.67 gain. Hope it keeps going.
G' day mates,
Aussie
SGN finished up $.11 or 25.58%. Won't make a prediction for tomorrow as the news today wasn't what one would call income producing. Have to wait to see what tomorrow brings. Charts don't favor an upward swing yet either.
G' day Mates,
Aussie
SGN up 20.93%. However, don't rush into it, as it had gone steadily down previously. Just one to watch. Went from $.43 to $.52.
G' day mates,
Aussie
AVANIR Announces Fiscal 2007 Fourth Quarter and Fiscal Year Financial Results
On Track with Zenvia™ Clinical Programs
AVANIR Pharmaceuticals (NASDAQ:AVNR) today reported unaudited financial results for the three and twelve months ended September 30, 2007.
For the fourth quarter of fiscal 2007, AVANIR reported a net profit of $12.1 million, or $0.28 per share, compared with a net loss of $22.2 million, or $0.70 per share, for the fourth quarter of fiscal 2006. The fourth quarter of fiscal 2007 net profit includes income from discontinued operations of approximately $12.0 million. Total net revenues from continuing operations for the fourth quarter of fiscal 2007 (excluding FazaClo net revenues) were $2.9 million compared with net revenues for the fourth quarter of fiscal 2006 of $2.2 million. Total operating expenses from continuing operations were $2.7 million in the fourth quarter of fiscal 2007, compared with $16.2 million in the comparable period in fiscal 2006. Operating expenses for the fourth quarter of fiscal 2006 included commercial development activities conducted in preparation for the anticipated Zenvia launch prior to receipt of the U.S. Food and Drug Administration (FDA) approvable letter.
"2007 has been a year of alignment and focus at AVANIR. We have created a foundation for success by gaining regulatory clarity and developing a path forward for the clinical development and future commercialization of our promising drug candidate Zenvia for the treatment of pseudobulbar affect (PBA) and for the treatment of diabetic peripheral neuropathic (DPN) pain," said Keith Katkin, AVANIR's President and CEO. "We have strengthened our financial position through the non-dilutive sale and licensing of non-core assets, restructured our operations to focus our resources on Zenvia, and begun our clinical and non-clinical activities to advance Zenvia in both PBA and DPN pain.
"We are making excellent progress on both our PBA and DPN pain clinical programs," said Randall Kaye, MD, Chief Medical Officer at AVANIR. "We have initiated patient enrollment in our confirmatory Phase III STAR trial with Zenvia in patients with PBA. As the next step in the Zenvia DPN pain program, we will utilize findings from a large, formal pharmacokinetic (PK) study to assess alternative lower-dose quinidine formulations of Zenvia designed to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication. We are pleased to announce that we have already initiated dosing in the first phase of the formal PK study and expect to release top-line results by the middle of calendar year 2008."
2007 FISCAL YEAR, RECENT HIGHLIGHTS AND UPCOMING MILESTONES:
CLINICAL PROGRAMS AND PIPELINE
Zenvia in PBA
Engaged in discussions with the FDA's Center for Drug Evaluation and Research, Division of Neurology Products and developed a PBA study protocol intended to address the issues raised by the FDA in its approvable letter of October 2006.
Reformulated Zenvia to develop a 30/10 mg (DM/Q) dose and a 20/10 mg dose.
Reached a definitive agreement with the FDA, under the special protocol assessment (SPA) process, on the design of a single confirmatory Phase III clinical trial with Zenvia in patients with PBA, referred to as the "STAR" trial.
Enrolled the first PBA patient into the confirmatory Phase III STAR trial. AVANIR expects to complete enrollment in approximately 15 to 18 months and report top-line results in the second half of calendar year 2009.
Zenvia in DPN Pain
Announced in April top-line results of a multi-center, three-month, double-blind Phase III trial. In this trial, treatment with Zenvia 45/30 mg dosed twice daily (DM/Q 45) and 30/30 mg dosed twice daily (DM/Q 30) were compared with placebo. Both doses of Zenvia met the primary endpoint of statistically significant improvement versus placebo as recorded in daily patient diary entries using the Pain Rating Scale, as specified in the SPA.
Presented primary and secondary endpoints of a Phase III study for Zenvia in DPN pain at the International Congress on Neuropathic Pain in Berlin in June. Results indicated that both doses of Zenvia demonstrated significantly superior reduction of pain compared with placebo. Additionally, Zenvia appeared generally safe and well tolerated, and safety data were consistent with previous clinical studies with no new safety signals noted. Furthermore, treatment with Zenvia provided significantly greater improvement compared with placebo in pain-related outcomes in patients with DPN pain, including pain relief, activity and sleep.
Requested a meeting with the FDA's Center for Drug Evaluation and Research, Division of Analgesics, Anesthetics and Rheumatology Products to discuss the protocol for a new Phase III study with Zenvia for the treatment of DPN pain. The FDA informed the Company that no meeting would be necessary and encouraged AVANIR to proceed directly with the development of a new Phase III DPN pain study protocol, as well as submit questions related to the clinical development program for Zenvia.
Initiated dosing in the first phase of the large, formal PK study that the Company is conducting to assess alternative lower-dose quinidine formulations of Zenvia designed to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication. AVANIR expects to release top-line results by the middle of calendar year 2008.
COMPANY OPERATIONS
Completed the previously announced sale of FazaClo to Azur Pharma Inc. and received an upfront payment of $42 million, plus an additional $1.9 million in working capital adjustments. Under the terms of the agreement, AVANIR could receive up to an additional $10 million in payments in 2009 contingent upon certain regulatory conditions, and up to $2 million in royalties, based on 3% of annualized net product revenues in excess of $17 million. A portion of the proceeds from the sale were used to pay down the Company's outstanding debt by $11 million, which is reflected on the Company's balance sheet for the year ending September 30, 2007. The Company believes that the net proceeds from the sale of FazaClo, plus the cash, cash equivalents and unrestricted investments in securities as of September 30, 2007 will be sufficient to finance operating expenses through the end of fiscal year 2008, including the initiation of the confirmatory Phase III STAR trial of Zenvia for patients with PBA and the completion of our ongoing PK study for DPN Pain.
Completed the closure of the San Diego drug discovery facility with associated reduction in headcount and payroll-related expenses, and signed a sublease agreement for that facility.
Received, in the fourth quarter of fiscal 2007, a $1.5 million milestone payment from Healthcare Brands International (HBI) for the first European regulatory approval of docosanol for marketing in Poland.
In November, received official communication from the European Patent Office (EPO), under Rule 51(4) EPC, that the EPO intends to grant our pending Zenvia patent for both PBA and DPN pain. Issuance of this patent will extend the patent life of Zenvia in Europe through 2023.
FISCAL 2007 FULL YEAR FINANCIAL RESULTS
For the fiscal year ended September 30, 2007, AVANIR reported a net loss of $20.9 million, or $0.53 per share, compared with a net loss of $62.6 million, or $2.04 per share for the prior fiscal year. The fiscal 2007 net loss includes income from discontinued operations of approximately $7.4 million. Total net revenues from continuing operations for fiscal 2007 (excluding FazaClo net revenues) were $9.2 million compared with net revenues for fiscal 2006 of $15.2 million. Total operating expenses from continuing operations were $34.5 million in fiscal 2007, compared with $59.4 million in fiscal 2006.
BALANCE SHEET HIGHLIGHTS
As of September 30, 2007, AVANIR had cash and investments in securities totaling $33.6 million, including cash and cash equivalents of $30.5 million, investments of $1.9 million and restricted investments in securities of $1.2 million.
Conference Call and Webcast
Management will host a conference call with a simultaneous webcast today beginning at 11:00 a.m. Eastern time / 8:00 a.m. Pacific time to discuss business developments in the fourth quarter of fiscal 2007. The call will feature Keith Katkin, President and Chief Executive Officer; Randall Kaye, MD, Senior Vice President and Chief Medical Officer; and Martin Sturgeon, Vice President and Interim Chief Financial Officer. Investors are invited to listen to the live webcast by visiting AVANIR's corporate website at www.avanir.com.
A webcast will be available on AVANIR's website for 30 days, and a telephone replay will be available through December 16, 2007, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 25259159.
About Zenvia
Zenvia is a combination of two well-characterized compounds: the therapeutically active ingredient dextromethorphan and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways: through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. In October 2006, the Company received an approvable letter for the treatment of Zenvia in PBA. The Company has initiated a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the FDA utilizing a new lower quinidine dose formulation of Zenvia to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. For more information about the Agency's SPA process see http://www.fda.gov/cder/guidance/3764fnl.htm. In April 2007 AVANIR announced successfully meeting all primary endpoints in the Phase III study of Zenvia in DPN pain. The Company is conducting a formal PK study to assess alternative lower-dose quinidine formulations of Zenvia for DPN pain that are intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication.
About AVANIR
AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system (CNS), inflammation and infectious diseases. In addition to Zenvia, which is in Phase III development for the treatment of PBA and DPN pain, AVANIR has also licensed a compound to Novartis International Pharmaceuticals Ltd. for the treatment of inflammatory disease. AVANIR's infectious disease drug candidate, AVP-21D9, is a human monoclonal antibody in pre-clinical development for the treatment of anthrax with funding provided to date from NIH/NIAID grants. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
Forward Looking Statements
Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that the proceeds received by the Company from the recent sale of the Company's FazaClo operations, together with the Company's other available funds, will be sufficient to fund the Company's operations as currently anticipated, or that the Company will be able to complete planned clinical trials within the projected time periods. There can also be no assurance that any additional Phase III trial for Zenvia will be successful, that any new doses of Zenvia will be safe and effective, or that the FDA will approve Zenvia for any indication. Risks and uncertainties affecting the Company's financial condition and operations also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent to update these forward-looking statements.
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website:
http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0
http://www.b2i.us/View.asp?b=958&ID=46932&I=30299
------------------------------------------------------
G' day Mates,
Aussie